Suven Life Sciences Initiates Phase I Clinical Trials In Europe Of SUVN-502 For Alzheimer's Disease
Added: 21 июня 2008
Last relative articles:
- Invest In A Future Without Dementia
- Advance Towards Early Alzheimer's Diagnosis
- Elan And Wyeth Announce Encouraging Top-line Results From Phase 2 Clinical Trial Of Bapineuzumab For Alzheimer's Disease
- Molecular Imaging Sheds New Light On Progression Of Alzheimer's Disease
- Known Genetic Risk For Alzheimer's In Whites Also Places Blacks At Risk
- UQ-US Team Targets Faster Alzheimer's Detection
- Researchers Link Memory Loss To Poor Diet
- New Campaign Launched In Wales: Are You Worried About Your Memory?
- The APCs Of Nerve Cell Function
- Potential New Role For Red Grape Seeds In Treatment Of Alzheimer's Disease
Comments: [0] / Post comment:
21 Nov 2008 07:11:41
Holy Land trial may have lasting effects - Dallas Morning News
Holy Land trial may have lasting effects Dallas Morning News, TX - They were acquitted in trials in Chicago and Florida on similar charges that they steered support to Palestinian terrorists. Mr. Ashqar was sentenced to 11 ...
20 Nov 2008 23:03:00
Attorney: Tampa trial puts Gotti at a disadvantage - The Associated Press
The Associated Press Attorney: Tampa trial puts Gotti at a disadvantage The Associated Press - (AP) Making John A. "Junior" Gotti stand trial on racketeering charges in Tampa instead of New York would be like "cutting off the supplies he needs to ... Prosecutors, defense make their case for where 'Junior' should be ...20 Nov 2008 20:19:33
Resolvyx moves dry eye drug from IND status to trials - Mass High Tech
Resolvyx moves dry eye drug from IND status to trials Mass High Tech, USA - This clears the company to proceed with trials . Resolvyx specializes in developing and commercializing resolvins. These are naturally occurring small ... Got Dry Eye? Take Fish Oil. Resolvyx Moves First Compound Into ... National Neurovision Research Institute (NNRI) and Resolvyx ... Resolvyx Announces Open IND for RX-10045, the Lead Resolvin ...
20 Nov 2008 19:00:49
Study Looks at Physicians' Likeliness To Refer Minority Patients ... - Kaiser network.org
Study Looks at Physicians' Likeliness To Refer Minority Patients ... Kaiser network.org, DC - "Factors Influencing Physician Referrals of Patients to Clinical Trials " (.pdf), Journal of the National Medical Association : The study, by University of ...
20 Nov 2008 16:35:03
Gloucester Pharmaceuticals to Present Positive Results from ... - MarketWatch
Gloucester Pharmaceuticals to Present Positive Results from ... MarketWatch - Numerous other trials are ongoing in additional indications including multiple myeloma. Over 750 patients, to date, have received romidepsin in clinical ...
20 Nov 2008 15:37:53
ImClone gets drug candidate manufacturing approval - Forbes
ImClone gets drug candidate manufacturing approval Forbes, NY - The drug is in mid-stage trials as a treatment for metastasized cancers of the skin, liver, lung, ovaries, prostate and kidneys. The company is enrolling ... ImClone Systems' State-of-the-Art Manufacturing Facility Receives ... Randomized Phase 2 Study Of IMC-A12 For HER2-Expressing Advanced ...
20 Nov 2008 15:01:59
SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776 ... - SYS-CON Media
SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776 ... SYS-CON Media, NJ - SuperGen will initiate a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of SGI-1776, a novel, orally administered, ...
20 Nov 2008 03:42:04
Takeda, Amgen to suspend trials of cancer drug - Reuters
SmartAboutHealth Takeda, Amgen to suspend trials of cancer drug Reuters - O: Quote, Profile, Research, Stock Buzz) said they would suspend enrolment in the last-stage trials of a key cancer drug candidate following negative study ... Amgen Drug for Lung Cancer Suspended After Deaths (Update3) Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of ... Safety fears derail late-stage Amgen cancer trial19 Nov 2008 17:59:00
Quintiles, SAS Announce Development of First-Ever Clinical Trials ... - MarketWatch
Quintiles, SAS Announce Development of First-Ever Clinical Trials ... MarketWatch - The Quintiles-SAS Clinical Trials Statistical Programming Certification will certify that the successful candidate has shown that he or she has the ...
19 Nov 2008 17:44:56
Nymox Announces NEXUS-1 and NEXUS-2 Phase 3 Trials for NX-1207 ... - MarketWatch
Nymox Announces NEXUS-1 and NEXUS-2 Phase 3 Trials for NX-1207 ... MarketWatch - is pleased to announce the NEXUS-1 and NEXUS-2 Phase 3 clinical trials for NX-1207, the Company's new drug for benign prostatic hyperplasia (BPH). ...